[Cryptococcosis in AIDS: therapeutic concepts] NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Cryptococcosis in AIDS: therapeutic concepts]

Mycoses. 1990;33 Suppl 1:55-64. Unique Identifier : AIDSLINE MED/91333670
Ruf B; II. Medizinische Klinik, Klinikums Rudolf Virchow (Wedding),; Freien Universitat Berlin.

Abstract: Cryptococcosis is the most common life-threatening mycosis with AIDS. The combination therapy based on amphotericin B and flucytosine is furthermore the therapy of first choice, even after introduction of fluconazole. With a therapy maintained over a period of 6 weeks the combination is nearly always successful; a shorter treatment period leads to minor treatment success. Since no elimination of the pathogen is possible in cryptococcosis with AIDS a permanent relapse prevention is necessary. In this prevention strategy fluconazole is highly effective and at present the drug of first choice; it is as effective as amphotericin B. An additional advantage is the possibility of oral application.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Amphotericin B/*THERAPEUTIC USE Cryptococcosis/COMPLICATIONS/*DRUG THERAPY/PREVENTION & CONTROL Drug Therapy, Combination English Abstract Fluconazole/*THERAPEUTIC USE Flucytosine/*THERAPEUTIC USE Human JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL

KWDacquiredimmunodeficiencysyndrome/KWDcomplicationsamphotericinb/KWDtherapeuticusecryptococcosis/complications/KWDdrugtherapy/prevention&controldrugtherapy,combinationenglishabstractfluconazole/KWDtherapeuticuseflucytosine/KWDtherapeuticusehumanjournalarticlereviewreview,tutorial
911130
M91B0790

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .